A Phase 1 interventional study of Oral hexavalent reassortant rotavirus attenuated live vaccine and Oral hexavalent reassortant rotavirus attenuated live vaccine in Rotavirus Gastroenteritis, sponsored by Sinovac Life Sciences Co., Ltd.. Completed at 1 site in China. Open to participants aged 6 Weeks to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Sinovac Life Sciences Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The Phase I clinical trial of the oral hexavalent reassortant rotavirus attenuated live vaccine (Vero Cells) will be conducted in a population ranging from 6 weeks to 59 years of age.
The objective of this study is to evaluate the safety of investigational vaccine in healthy adults and children, as well as its safety tolerability, and immunogenicity in healthy infants.
The study will be an open-label observation in adults and children, and a randomized, double-blind, placebo-controlled clinical trial in infants.
The Phase I clinical trial is an open-label observation involving healthy adults and children, as well as a randomized, double-blind, placebo-controlled study in healthy infants to evaluate the safety, tolerability, and immunogenicity of the investigaional vaccine. The investigational vaccine is available in both high-dose and low-dose formulations. The placebo is identical to the trial vaccine in all components except for the rotavirus.
This study will enroll 100 participants, consisting of 20 adults aged 18-59 years, 20 children aged 2-6 years, and 60 infants aged 6-12 weeks. Participants will be enrolled sequentially, starting with adults, followed by children, and then infants. Enrollment for the subsequent group will begin after a 14-day safety observation period and confirmation of acceptable safety in the preceding group. Adult and child participants will receive the investigational vaccine in an open-label manner. The infants will be enrolled into two cohorts of 30 participants each: a low-dose cohort and a high-dose cohort. Within each cohort, the infants will be randomly assigned to two groups at a ratio of 2:1 and will receive either the investigational vaccine or a placebo in a double-blind manner. The immunization schedule for both the vaccine and placebo consists of three doses administered at 28-day intervals.
Adverse events (AE) will be collected for all participants until 42 days after the last dose vaccination. Stool samples will be collected after each vaccination to detect vaccine strain shedding among infant participants. Serious adverse events (SAE) will be observed for 6 months from the last dose for adults and children or 12 months for infants. Blood samples from the infants will be collected at predetermined times to evaluate the immunogenicity of the investigational vaccine.
237 studies on the registry are indexed under Gastroenteritis; 16 are open to participants now.
This study's enrollment of 100 is below the median of 136 across 164 interventional studies indexed under Gastroenteritis.
Browse Gastroenteritis studies →Sinovac Life Sciences Co., Ltd. is the lead sponsor of 26 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clinical laboratory tests showing laboratory abnormalities beyond the reference range that are (for adult and pediatric groups):
Additional Exclusion Criteria for Infants Aged 6 to 12 Weeks
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The experimental vaccine will be administered in three doses, with a 28-day interval between each dose.
Biological: Oral hexavalent reassortant rotavirus attenuated live vaccine
The experimental vaccine will be administered in three doses, with a 28-day interval between each dose
Biological: Oral hexavalent reassortant rotavirus attenuated live vaccine
They will receive three low-dose experimental vaccine in a double-blind setting, with a 28-day interval between each dose.
Biological: Oral hexavalent reassortant rotavirus attenuated live vaccine
They will receive three doses of the placebo in a double-blind setting, with a 28-day interval between each dose
Biological: Placebo
They will receive three high-dose experimental vaccine in a double-blind setting, with a 28-day interval between each dose
Biological: Oral hexavalent reassortant rotavirus attenuated live vaccine
They will receive three doses of the placebo in a double-blind setting,with a 28-day interval between each dose
Biological: Placebo
Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally
Placebo of experimental vaccine for infants three doses administered orally
Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
Placebo of experimental vaccine for infants three doses administered orally
Evaluate the safety of the investigational vaccine
Incidence of adverse events/reactions
Time frame: 0 day after the first dose till 42 days after the last dose
Evaluate the safety of the investigational vaccine
Incidence of adverse events/reactions
Time frame: 0-14 days after each dose
Evaluate the safety of the investigational vaccine
Incidence of adverse events/reactions
Time frame: 0-30 minutes after each dose
Evaluate the safety of the investigational vaccine in the healthy adults and children groups
Incidence of clinically significant abnormal laboratory parameters on day 3 after each dose in adult and children groups
Time frame: day 3 after each dose
Evaluate the safety of the investigational vaccine
Incidence of serious adverse events (SAEs)
Time frame: Within 6 months after the last dose
Evaluate the safety of the investigational vaccine in the healthy infant group
Incidence of serious adverse events (SAEs) and adverse events of special interest (AESIs)
Time frame: Within 12 months after the last dose in the infant group
Evaluate the immunogenicity and immune persistence of the investigated vaccine in healthy infants.
Seroconversion rate of serum IgA antibodies against vaccine serotype rotavirus.
Time frame: 28 days after the full vaccination course
Evaluate the immunogenicity and immune persistence of the investigated vaccine in healthy infants.
Seropositivity rate of serum IgA antibodies against vaccine serotype rotavirus.
Time frame: 28 days after the full vaccination course
Evaluate the immunogenicity and immune persistence of the investigated vaccine in healthy infants.
Geometric mean concentration (GMC) of serum IgA antibodies against vaccine serotype rotavirus.
Time frame: 28 days after the full vaccination course
Evaluate the immunogenicity and immune persistence of the investigated vaccine in healthy infants.
Geometric mean increase (GMI) of serum IgA antibodies against vaccine serotype rotavirus.
Time frame: 28 days after the full vaccination course
Evaluate the immunogenicity and immune persistence of the investigated vaccine in healthy infants.
Seropositivity rate of serum IgA antibodies against vaccine serotype rotavirus
Time frame: 6 months and 12 months after the full vaccination course
Evaluate the immunogenicity and immune persistence of the investigated vaccine in healthy infants.
Geometric mean concentration (GMC) of serum IgA antibodies against vaccine serotype rotavirus
Time frame: 6 months and 12 months after the full vaccination course
Evaluate the fecal shedding of investigated vaccine strain in healthy infants after vaccination.
The shedding rate of the rotavirus vaccine strain in the stool.
Time frame: 0-14 days after each dose
Evaluate the fecal shedding of investigated vaccine strain in healthy infants after vaccination.
The shedding duration of the rotavirus vaccine strain in the stool.
Time frame: 0-14 days after each dose
Evaluate the reassortment and reversion of the rotavirus vaccine strain in stool samples of healthy infants after vaccination
The incidence of reassortment and reversion of the rotavirus vaccine strain in stool samples.
Time frame: 0-14 days after each dose,
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Dec 2024, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sinovac Life Sciences Co., Ltd. →